EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia



Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia



Blood 94(6): 1840-1847



Cellular immunophenotypic studies were performed on a cohort of randomly selected IgM(+) B-chronic lymphocytic leukemia (B-CLL) cases for which Ig V(H) and V(L) gene sequences were available. The cases were categorized based on V gene mutation status and CD38 expression and analyzed for treatment history and survival. The B-CLL cases could be divided into 2 groups. Those patients with unmutated V genes displayed higher percentages of CD38(+) B-CLL cells (>/=30%) than those with mutated V genes that had lower percentages of CD38(+) cells (<30%). Patients in both the unmutated and the >/=30% CD38(+) groups responded poorly to continuous multiregimen chemotherapy (including fludarabine) and had shorter survival. In contrast, the mutated and the <30% CD38(+) groups required minimal or no chemotherapy and had prolonged survival. These observations were true also for those patients who stratified to the Rai intermediate risk category. In the mutated and the <30% CD38(+) groups, males and females were virtually equally distributed, whereas in the unmutated and the >/=30% CD38(+) groups, a marked male predominance was found. Thus, Ig V gene mutation status and the percentages of CD38(+) B-CLL cells appear to be accurate predictors of clinical outcome in B-CLL patients. These parameters, especially CD38 expression that can be analyzed conveniently in most clinical laboratories, should be valuable adjuncts to the present staging systems for predicting the clinical course in individual B-CLL cases. Future evaluations of new therapeutic strategies and drugs should take into account the different natural histories of patients categorized in these manners.

(PDF emailed within 1 workday: $29.90)

Accession: 010791208

Download citation: RISBibTeXText

PMID: 10477712



Related references

Differential signaling via surface IgM is associated with VH gene mutation status and CD38 expression in chronic lymphocytic leukemia. British Journal of Cancer 88(Supplement 1): S67, July, 2003

CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemia. Blood 97(6): 1902-1903, 2001

V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100(4): 1410-1416, 2002

CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99(3): 1023-1029, 2002

CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. Blood 97(6): 1892-1894, 2001

Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 101(3): 1087-1093, 2002

Gene Expression Profiling in CD38+ Versus CD38- B Cell Chronic Lymphocytic Leukemia. Blood 100(11): Abstract No 1480, November 16, 2002

Quantitative CD38 and IgVH genes mutation status in B cell chronic lymphocytic leukemia. Blood 102(11): 353b, November 16, 2003

The prognostic value of CD38 expression and its quantification in B cell chronic lymphocytic leukemia (B-CLL). Leukemia & Lymphoma 45(3): 455-462, 2004

The Prognostic Significance of Combined Expression of ZAP-70 and CD38 in Chronic Lymphocytic Leukemia. Journal of the Egyptian National Cancer Institute 21(4): 287-297, 2009

Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood 100(4): 1404-1409, 2002

Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. Blood 105(12): 4807-4812, 2005

Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 112(5): 1923-1930, 2008

CD38 expression identifies two distinct prognostic subsets in B-chronic lymphocytic leukemia. Blood 96(11 Part 1): 366a-367a, November 16, 2000

CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 98(1): 181-186, July 1, 2001